Literature DB >> 21911262

Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies.

Alfonso Fasano, Magda D'Agostino, Giacomo Caldarola, Claudio Feliciani, Clara De Simone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21911262     DOI： 10.1016/j.jneuroim.2011.08.014

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


× No keyword cloud information.
  5 in total

1.  Behcet's disease.

Authors:  Jagdish R Nair; Robert J Moots
Journal:  Clin Med (Lond)       Date:  2017-02       Impact factor: 2.659

2.  Longitudinal Myelitis of a Neuro-Behçet Patient.

Authors:  Qi Tang; Jing Tian
Journal:  Arch Rheumatol       Date:  2015-11-03       Impact factor: 1.472

Review 3.  Update on the diagnosis and management of Behçet's disease.

Authors:  Ryo Rokutanda; Mitsumasa Kishimoto; Masato Okada
Journal:  Open Access Rheumatol       Date:  2014-12-30

Review 4.  Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations.

Authors:  Seema Kalra; Alan Silman; Gulsen Akman-Demir; Saeed Bohlega; Afshin Borhani-Haghighi; Cris S Constantinescu; Habib Houman; Alfred Mahr; Carlos Salvarani; Petros P Sfikakis; Aksel Siva; Adnan Al-Araji
Journal:  J Neurol       Date:  2013-12-24       Impact factor: 4.849

5.  Infliximab is a plausible alternative for neurologic complications of Behçet disease.

Authors:  Burcu Zeydan; Ugur Uygunoglu; Sabahattin Saip; Onat N Demirci; Emire Seyahi; Serdal Ugurlu; Vedat Hamuryudan; Aksel Siva; Orhun H Kantarci
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.